{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T12:37:39Z","timestamp":1793277459405,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:00:00Z","timestamp":1793232000000},"content-version":"vor","delay-in-days":117,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04354-7","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T11:44:26Z","timestamp":1783165466000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Macrophage heterogeneity in breast cancer microenvironment and development of a prognostic model: exploring TFF1 as a novel therapeutic target"],"prefix":"10.1007","volume":"75","author":[{"given":"Lin","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bailu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingli","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoren","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,4]]},"reference":[{"issue":"1","key":"4354_CR1","first-page":"7","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin 72(1):7\u201333","journal-title":"CA Cancer J Clin"},{"key":"4354_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22179644","author":"J An","year":"2021","unstructured":"An J, Peng C, Tang H, Liu X, Peng F (2021) New advances in the research of resistance to neoadjuvant chemotherapy in breast cancer. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22179644","journal-title":"Int J Mol Sci"},{"issue":"8","key":"4354_CR3","volume":"13","author":"SW Ruo","year":"2021","unstructured":"Ruo SW, Alkayyali T, Win M, Tara A, Joseph C, Kannan A, Srivastava K, Ochuba O, Sandhu JK, Went TR et al (2021) Role of gut microbiota dysbiosis in breast cancer and novel approaches in prevention, diagnosis, and treatment. Cureus 13(8):e17472","journal-title":"Cureus"},{"issue":"8","key":"4354_CR4","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41568-020-0266-x","volume":"20","author":"KL Britt","year":"2020","unstructured":"Britt KL, Cuzick J, Phillips KA (2020) Key steps for effective breast cancer prevention. Nat Rev Cancer 20(8):417\u2013436","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"4354_CR5","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","volume":"321","author":"AG Waks","year":"2019","unstructured":"Waks AG, Winer EP (2019) Breast cancer treatment: a review. JAMA 321(3):288\u2013300","journal-title":"JAMA"},{"issue":"5","key":"4354_CR6","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2174\/0113892029305656240503045154","volume":"25","author":"MS Hussain","year":"2024","unstructured":"Hussain MS, Agrawal M, Shaikh NK, Saraswat N, Bahl G, Maqbool Bhat M, Khurana N, Bisht AS, Tufail M, Kumar R (2024) Beyond the genome: deciphering the role of MALAT1 in breast cancer progression. Curr Genomics 25(5):343\u2013357","journal-title":"Curr Genomics"},{"issue":"9","key":"4354_CR7","doi-asserted-by":"publisher","first-page":"681","DOI":"10.2174\/0109298665322427240906060626","volume":"31","author":"V Torun","year":"2024","unstructured":"Torun V, Degerli E, Cansaran-Duman D (2024) Revealing the molecular signatures of miR-185-5p on breast cancer cells using proteomic analysis. Protein Pept Lett 31(9):681\u2013695","journal-title":"Protein Pept Lett"},{"key":"4354_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.978909","volume":"13","author":"S Song","year":"2022","unstructured":"Song S, Zhang M, Xie P, Wang S, Wang Y (2022) Comprehensive analysis of cuproptosis-related genes and tumor microenvironment infiltration characterization in breast cancer. Front Immunol 13:978909","journal-title":"Front Immunol"},{"issue":"3","key":"4354_CR9","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2174\/0109298665339026250114070523","volume":"32","author":"X Li","year":"2025","unstructured":"Li X, Liu J, He L, Tian M, Xu Y, Peng B (2025) miR-584-5p regulates MSMO1 to modulate the AKT\/PI3K pathway and inhibit breast cancer progression. Protein Pept Lett 32(3):171\u2013182","journal-title":"Protein Pept Lett"},{"key":"4354_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123863","author":"F Fico","year":"2020","unstructured":"Fico F, Santamaria-Mart\u00ednez A (2020) The tumor microenvironment as a driving force of breast cancer stem cell plasticity. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers12123863","journal-title":"Cancers (Basel)"},{"issue":"4","key":"4354_CR11","doi-asserted-by":"publisher","first-page":"312","DOI":"10.2174\/0113892029358348250124064940","volume":"26","author":"H Gou","year":"2025","unstructured":"Gou H, Yang H, Cheng J, He S, Luo C, Chen X, Zhong X (2025) YY2 serves as a novel prognostic biomarker correlated with immune microenvironment and glycolysis in esophageal carcinoma. Curr Genomics 26(4):312\u2013328","journal-title":"Curr Genomics"},{"issue":"1","key":"4354_CR12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41467-017-02481-5","volume":"9","author":"N Linde","year":"2018","unstructured":"Linde N, Casanova-Acebes M, Sosa MS, Mortha A, Rahman A, Farias E, Harper K, Tardio E, Reyes Torres I, Jones J et al (2018) Macrophages orchestrate breast cancer early dissemination and metastasis. Nat Commun 9(1):21","journal-title":"Nat Commun"},{"issue":"1","key":"4354_CR13","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","volume":"41","author":"R Noy","year":"2014","unstructured":"Noy R, Pollard JW (2014) Tumor-associated macrophages: from mechanisms to therapy. Immunity 41(1):49\u201361","journal-title":"Immunity"},{"key":"4354_CR14","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.ctrv.2018.08.010","volume":"70","author":"SQ Qiu","year":"2018","unstructured":"Qiu SQ, Waaijer SJH, Zwager MC, de Vries EGE, van der Vegt B, Schr\u00f6der CP (2018) Tumor-associated macrophages in breast cancer: innocent bystander or important player? Cancer Treat Rev 70:178\u2013189","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"4354_CR15","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1136\/jclinpath-2011-200355","volume":"65","author":"SM Mahmoud","year":"2012","unstructured":"Mahmoud SM, Lee AH, Paish EC, Macmillan RD, Ellis IO, Green AR (2012) Tumour-infiltrating macrophages and clinical outcome in breast cancer. J Clin Pathol 65(2):159\u2013163","journal-title":"J Clin Pathol"},{"issue":"7","key":"4354_CR16","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","volume":"14","author":"A Mantovani","year":"2017","unstructured":"Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P (2017) Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol 14(7):399\u2013416","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"4354_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/cas.12314","volume":"105","author":"Y Komohara","year":"2014","unstructured":"Komohara Y, Jinushi M, Takeya M (2014) Clinical significance of macrophage heterogeneity in human malignant tumors. Cancer Sci 105(1):1\u20138","journal-title":"Cancer Sci"},{"issue":"3","key":"4354_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7053","volume":"13","author":"AK Elfstrum","year":"2024","unstructured":"Elfstrum AK, Bapat AS, Schwertfeger KL (2024) Defining and targeting macrophage heterogeneity in the mammary gland and breast cancer. Cancer Med 13(3):e7053","journal-title":"Cancer Med"},{"issue":"11","key":"4354_CR19","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","volume":"21","author":"A Mantovani","year":"2022","unstructured":"Mantovani A, Allavena P, Marchesi F, Garlanda C (2022) Macrophages as tools and targets in cancer therapy. Nat Rev Drug Discov 21(11):799\u2013820","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"4354_CR20","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.cmp.2025.06.002","volume":"18","author":"Y Li","year":"2025","unstructured":"Li Y, Chen R, Zhang L, Jiang Y, Ren S, Li S, Xu H, Tan Y, Chen S, Tan X et al (2025) Intra-tumor DKK1 and CALML5 heterogeneity as a novel biomarker for prognosis and immunotherapy response in head and neck squamous cell carcinoma. Curr Mol Pharmacol 18(1):6\u201321","journal-title":"Curr Mol Pharmacol"},{"issue":"1","key":"4354_CR21","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.cmp.2025.11.002","volume":"18","author":"HM Ismail","year":"2025","unstructured":"Ismail HM, Attia AA, Abdelaal A, Youness RA (2025) MIAT, HEIH, and HOTAIR: a novel LncRNA signature in non-metastatic hepatocellular carcinoma patients. Curr Mol Pharmacol 18(1):83\u201392","journal-title":"Curr Mol Pharmacol"},{"issue":"7","key":"4354_CR22","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","volume":"177","author":"T Stuart","year":"2019","unstructured":"Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck WM 3rd, Hao Y, Stoeckius M, Smibert P, Satija R (2019) Comprehensive integration of single-cell data. Cell 177(7):1888-1902.e1821","journal-title":"Cell"},{"key":"4354_CR23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3346\/jkms.2007.22.S.S17","volume":"22","author":"J Choi","year":"2007","unstructured":"Choi J, Hwang YK, Choi YJ, Yoo KE, Kim JH, Nam SJ, Yang JH, Lee SJ, Yoo KH, Sung KW et al (2007) Neuronal apoptosis inhibitory protein is overexpressed in patients with unfavorable prognostic factors in breast cancer. J Korean med sci 22:17\u201323","journal-title":"J Korean med sci"},{"issue":"1","key":"4354_CR24","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/s41401-019-0228-6","volume":"41","author":"Y Liu","year":"2020","unstructured":"Liu Y, Grimm M, Dai WT, Hou MC, Xiao ZX, Cao Y (2020) CB-Dock: a web server for cavity detection-guided protein-ligand blind docking. Acta Pharmacol Sin 41(1):138\u2013144","journal-title":"Acta Pharmacol Sin"},{"issue":"12","key":"4354_CR25","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1093\/bioinformatics\/btu104","volume":"30","author":"Y Cao","year":"2014","unstructured":"Cao Y, Li L (2014) Improved protein-ligand binding affinity prediction by using a curvature-dependent surface-area model. Bioinformatics 30(12):1674\u20131680","journal-title":"Bioinformatics"},{"issue":"1","key":"4354_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/ni.3320","volume":"17","author":"Y Okabe","year":"2016","unstructured":"Okabe Y, Medzhitov R (2016) Tissue biology perspective on macrophages. Nat Immunol 17(1):9\u201317","journal-title":"Nat Immunol"},{"issue":"7446","key":"4354_CR27","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nature12034","volume":"496","author":"TA Wynn","year":"2013","unstructured":"Wynn TA, Chawla A, Pollard JW (2013) Macrophage biology in development, homeostasis and disease. Nature 496(7446):445\u2013455","journal-title":"Nature"},{"issue":"3","key":"4354_CR28","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ccr.2013.02.013","volume":"23","author":"M De Palma","year":"2013","unstructured":"De Palma M, Lewis CE (2013) Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 23(3):277\u2013286","journal-title":"Cancer Cell"},{"issue":"3","key":"4354_CR29","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/path.1711720302","volume":"172","author":"C O'Sullivan","year":"1994","unstructured":"O\u2019Sullivan C, Lewis CE (1994) Tumour-associated leucocytes: friends or foes in breast carcinoma. J Pathol 172(3):229\u2013235","journal-title":"J Pathol"},{"issue":"23","key":"4354_CR30","doi-asserted-by":"publisher","first-page":"6631","DOI":"10.1016\/j.cell.2024.09.016","volume":"187","author":"E Dalla","year":"2024","unstructured":"Dalla E, Papanicolaou M, Park MD, Barth N, Hou R, Segura-Villalobos D, Valencia Salazar L, Sun D, Forrest ARR, Casanova-Acebes M et al (2024) Lung-resident alveolar macrophages regulate the timing of breast cancer metastasis. Cell 187(23):6631-6648.e6620","journal-title":"Cell"},{"issue":"8","key":"4354_CR31","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1189052","volume":"5","author":"B Nandi","year":"2016","unstructured":"Nandi B, Shapiro M, Samur MK, Pai C, Frank NY, Yoon C, Prabhala RH, Munshi NC, Gold JS (2016) Stromal CCR6 drives tumor growth in a murine transplantable colon cancer through recruitment of tumor-promoting macrophages. Oncoimmunology 5(8):e1189052","journal-title":"Oncoimmunology"},{"issue":"1","key":"4354_CR32","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/CJI.0b013e3181b7a0a4","volume":"33","author":"CH Lee","year":"2010","unstructured":"Lee CH, Wu CL, Shiau AL (2010) Toll-like receptor 4 signaling promotes tumor growth. J Immunother 33(1):73\u201382","journal-title":"J Immunother"},{"issue":"5","key":"4354_CR33","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1369\/jhc.6A7100.2007","volume":"55","author":"J Madsen","year":"2007","unstructured":"Madsen J, Nielsen O, Torn\u00f8e I, Thim L, Holmskov U (2007) Tissue localization of human trefoil factors 1, 2, and 3. J Histochem Cytochem 55(5):505\u2013513","journal-title":"J Histochem Cytochem"},{"issue":"5","key":"4354_CR34","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s00428-005-1240-4","volume":"446","author":"P Kornprat","year":"2005","unstructured":"Kornprat P, Rehak P, Lemmerer M, Gogg-Kamerer M, Langner C (2005) Analysis of trefoil factor family protein 1 (TFF1, pS2) expression in chronic cholecystitis and gallbladder carcinoma. Virchows Arch 446(5):505\u2013510","journal-title":"Virchows Arch"},{"issue":"5","key":"4354_CR35","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.pan.2017.07.188","volume":"17","author":"M Sunagawa","year":"2017","unstructured":"Sunagawa M, Yamaguchi J, Kokuryo T, Ebata T, Yokoyama Y, Sugawara G, Nagino M (2017) Trefoil factor family 1 expression in the invasion front is a poor prognostic factor associated with lymph node metastasis in pancreatic cancer. Pancreatology 17(5):782\u2013787","journal-title":"Pancreatology"},{"issue":"3","key":"4354_CR36","doi-asserted-by":"publisher","first-page":"894","DOI":"10.3892\/ijo.2013.1759","volume":"42","author":"T Tanaka","year":"2013","unstructured":"Tanaka T, Nakamura J, Kitajima Y, Kai K, Miyake S, Hiraki M, Ide T, Koga Y, Noshiro H (2013) Loss of trefoil factor 1 is regulated by DNA methylation and is an independent predictive factor for poor survival in advanced gastric cancer. Int J Oncol 42(3):894\u2013902","journal-title":"Int J Oncol"},{"issue":"1","key":"4354_CR37","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/01.pai.0000141544.28862.35","volume":"14","author":"B Tuna","year":"2006","unstructured":"Tuna B, S\u00f6kmen S, Sario\u011flu S, F\u00fcz\u00fcn M, K\u00fcpelio\u011flu A, Ellidokuz H (2006) PS2 and HSP70 expression in rectal adenocarcinomas: an immunohistochemical investigation of 45 cases. Appl Immunohistochem Mol Morphol 14(1):31\u201336","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"9","key":"4354_CR38","doi-asserted-by":"publisher","first-page":"R66","DOI":"10.1186\/gb-2004-5-9-r66","volume":"5","author":"CY Lin","year":"2004","unstructured":"Lin CY, Str\u00f6m A, Vega VB, Kong SL, Yeo AL, Thomsen JS, Chan WC, Doray B, Bangarusamy DK, Ramasamy A et al (2004) Discovery of estrogen receptor alpha target genes and response elements in breast tumor cells. Genome Biol 5(9):R66","journal-title":"Genome Biol"},{"issue":"10","key":"4354_CR39","doi-asserted-by":"publisher","first-page":"4473","DOI":"10.1210\/en.2009-0066","volume":"150","author":"N Amiry","year":"2009","unstructured":"Amiry N, Kong X, Muniraj N, Kannan N, Grandison PM, Lin J, Yang Y, Vouyovitch CM, Borges S, Perry JK et al (2009) Trefoil factor-1 (TFF1) enhances oncogenicity of mammary carcinoma cells. Endocrinology 150(10):4473\u20134483","journal-title":"Endocrinology"},{"issue":"5","key":"4354_CR40","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1158\/1541-7786.MCR-18-1039","volume":"17","author":"HJ Pegg","year":"2019","unstructured":"Pegg HJ, Harrison H, Rogerson C, Shore P (2019) The RUNX transcriptional coregulator, CBF\u03b2, suppresses migration of ER(+) breast cancer cells by repressing ER\u03b1-mediated expression of the migratory factor TFF1. Mol Cancer Res 17(5):1015\u20131023","journal-title":"Mol Cancer Res"},{"issue":"6","key":"4354_CR41","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1096\/fj.01-0498fje","volume":"16","author":"SJ Prest","year":"2002","unstructured":"Prest SJ, May FE, Westley BR (2002) The estrogen-regulated protein, TFF1, stimulates migration of human breast cancer cells. FASEB J 16(6):592\u2013594","journal-title":"FASEB J"},{"issue":"8","key":"4354_CR42","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.cpan.2025.09.001","volume":"21","author":"H Liu","year":"2025","unstructured":"Liu H, He Y, Sun B, Xu Z, Fan Y, Sun J (2025) Network pharmacology, molecular docking, and molecular dynamics simulation in drug development: a comprehensive perspective. Curr Pharm Anal 21(8):402\u2013405","journal-title":"Curr Pharm Anal"},{"issue":"7","key":"4354_CR43","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.cpan.2025.06.002","volume":"21","author":"S Ren","year":"2025","unstructured":"Ren S, Zhu Q, Yang Z, Wang Y, Li Z, Bian H, Tan J (2025) Exploring the potential mechanism of the active components of Rhizoma Coptidis in tendinopathy treatment applying network pharmacology and molecular docking analysis. Curr Pharm Anal 21(7):337\u2013348","journal-title":"Curr Pharm Anal"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04354-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04354-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04354-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T12:21:02Z","timestamp":1793276462000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04354-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,4]]},"references-count":43,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["4354"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04354-7","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,4]]},"assertion":[{"value":"27 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has not been published before, and all authors approved this publication.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has been approved by the Ethics Committee of Jiangsu Cancer Hospital.","order":3,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"261"}}